New Treatments for Uterine Fibroids
In this prospective, open-label, single-arm trial of 149 individuals with heavy menstrual bleeding and uterine leiomyomas, daily relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) resulted in a mean menstrual blood loss reduction of 90%, and 70% of the participants achieved amenorrhea by the end of the 52-week period. Similar results were found for other arms of the trial among women who crossed over from placebo and relugolix-only therapy to relugolix combination therapy.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.